Loestrin transaction gets further FTC scrutiny
Executive Summary
FTC has requested additional information on Barr's proposed acquisition of rights to Galen's Loestrin oral contraceptive line (1"The Pink Sheet" Sept. 15, 2003, p. 37). Barr had hoped to close the deal by Feb. 1; the company is "unable to determine the impact" of FTC's request for additional information...
You may also be interested in...
Galen Settles Estrostep, FemHRT Litigation, Barr Picks Up Loestrin In Deal
A product licensing agreement between Galen and Barr will settle FemHRT and Estrostep patent litigation inherited by Galen from Pfizer
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.